Description
Description
This page contains brief details about the drug darbepoetin alfa, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Darbepoetin Alfa is a medication indicated to treat anaemia. It was approved for its medical use on 17th September 2001.
Mechanism of Action of Darbepoetin Alfa
Darbepoetin Alfa Injection is a biological agent that works to treat anaemia. It is produced by gene-technology in Chinese hamster ovary cells and acts in the same way as the hormone erythropoietin synthesized by the kidneys. It induces the bone marrow to produce more red blood cells and eventually reduces anaemia.
Uses of Darbepoetin Alfa
Darbepoetin Alfa Injection has been developed to treat anaemia in children and adults with chronic kidney disease (renal failure) and those receiving chemotherapy for non-bone marrow cancers.
Darbepoetin Alfa Dosage available
Darbepoetin alfa is available in injection form in the doses 25mcg, 40mcg, 60mcg, 100mcg, 200mcg, 500mcg. Your physician will calculate the accurate dose after monitoring your blood counts.
For chronic renal failure, the initial recommended dose is 0.75mcg/kg bodyweight every two weeks or 0.45mcg/kg bodyweight weekly once. For patients not on dialysis the ideal dose is 1.5mcg/kg bodyweight once monthly.
For patients undergoing chemotherapy treatment, the recommended dose is 500mcg once every three weeks or 2.25mcg once weekly.
